Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study.
Alcohol use disorder
Alcohol withdrawal syndrome
Alcohol-associated hepatitis
Benzodiazepines
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
21
11
2022
revised:
29
05
2023
accepted:
31
05
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
The prevalence and impact of alcohol withdrawal syndrome (AWS) in patients with alcohol-associated hepatitis (AH) are unknown. In this study, we aimed to investigate the prevalence, predictors, management, and clinical impact of AWS in patients hospitalized with AH. A multinational, retrospective cohort study enrolling patients hospitalized with AH at 5 medical centres in Spain and in the USA was performed between January 1st, 2016 to January 31st, 2021. Data were retrospectively retrieved from electronic health records. Diagnosis of AWS was based on clinical criteria and use of sedatives to control AWS symptoms. The primary outcome was mortality. Multivariable models controlling for demographic variables and disease severity were performed to determine predictors of AWS (adjusted odds ratio [OR]) and the impact of AWS condition and management on clinical outcomes (adjusted hazard ratio [HR]). In total, 432 patients were included. The median MELD score at admission was 21.9 (18.3-27.3). The overall prevalence of AWS was 32%. Lower platelet levels (OR = 1.61, 95% CI 1.05-2.48) and previous history of AWS (OR = 2.09, 95% CI 1.31-3.33) were associated with a higher rate of incident AWS, whereas the use of prophylaxis decreased the risk (OR = 0.58, 95% CI 0.36-0.93). The use of intravenous benzodiazepines (HR = 2.18, 95% CI 1.02-4.64) and phenobarbital (HR = 2.99, 95% CI 1.07-8.37) for AWS treatment were independently associated with a higher mortality. The development of AWS increased the rate of infections (OR = 2.24, 95% CI 1.44-3.49), the need for mechanical ventilation (OR = 2.49, 95% CI 1.38-4.49), and ICU admission (OR = 1.96, 95% CI 1.19-3.23). Finally, AWS was associated with higher 28-day (HR = 2.31, 95% CI 1.40-3.82), 90-day (HR = 1.78, 95% CI 1.18-2.69), and 180-day mortality (HR = 1.54, 95% CI 1.06-2.24). AWS commonly occurs in patients hospitalized with AH and complicates the hospitalization course. Routine prophylaxis is associated with a lower prevalence of AWS. Prospective studies should determine diagnostic criteria and prophylaxis regimens for AWS management in patients with AH. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Sections du résumé
Background
UNASSIGNED
The prevalence and impact of alcohol withdrawal syndrome (AWS) in patients with alcohol-associated hepatitis (AH) are unknown. In this study, we aimed to investigate the prevalence, predictors, management, and clinical impact of AWS in patients hospitalized with AH.
Methods
UNASSIGNED
A multinational, retrospective cohort study enrolling patients hospitalized with AH at 5 medical centres in Spain and in the USA was performed between January 1st, 2016 to January 31st, 2021. Data were retrospectively retrieved from electronic health records. Diagnosis of AWS was based on clinical criteria and use of sedatives to control AWS symptoms. The primary outcome was mortality. Multivariable models controlling for demographic variables and disease severity were performed to determine predictors of AWS (adjusted odds ratio [OR]) and the impact of AWS condition and management on clinical outcomes (adjusted hazard ratio [HR]).
Findings
UNASSIGNED
In total, 432 patients were included. The median MELD score at admission was 21.9 (18.3-27.3). The overall prevalence of AWS was 32%. Lower platelet levels (OR = 1.61, 95% CI 1.05-2.48) and previous history of AWS (OR = 2.09, 95% CI 1.31-3.33) were associated with a higher rate of incident AWS, whereas the use of prophylaxis decreased the risk (OR = 0.58, 95% CI 0.36-0.93). The use of intravenous benzodiazepines (HR = 2.18, 95% CI 1.02-4.64) and phenobarbital (HR = 2.99, 95% CI 1.07-8.37) for AWS treatment were independently associated with a higher mortality. The development of AWS increased the rate of infections (OR = 2.24, 95% CI 1.44-3.49), the need for mechanical ventilation (OR = 2.49, 95% CI 1.38-4.49), and ICU admission (OR = 1.96, 95% CI 1.19-3.23). Finally, AWS was associated with higher 28-day (HR = 2.31, 95% CI 1.40-3.82), 90-day (HR = 1.78, 95% CI 1.18-2.69), and 180-day mortality (HR = 1.54, 95% CI 1.06-2.24).
Interpretation
UNASSIGNED
AWS commonly occurs in patients hospitalized with AH and complicates the hospitalization course. Routine prophylaxis is associated with a lower prevalence of AWS. Prospective studies should determine diagnostic criteria and prophylaxis regimens for AWS management in patients with AH.
Funding
UNASSIGNED
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Identifiants
pubmed: 37415844
doi: 10.1016/j.eclinm.2023.102046
pii: S2589-5370(23)00223-7
pmc: PMC10319982
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102046Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest regarding this manuscript.
Références
JAMA. 2018 Aug 28;320(8):825-833
pubmed: 30167704
Hepatology. 2015 Sep;62(3):762-72
pubmed: 25761863
Clin Liver Dis. 2019 Feb;23(1):39-50
pubmed: 30454831
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Br J Anaesth. 1995 Dec;75(6):734-9
pubmed: 8672322
Alcohol. 2014 Jun;48(4):375-90
pubmed: 24657098
Emerg Med J. 2012 Oct;29(10):802-4
pubmed: 22011975
Injury. 2022 Jan;53(1):44-48
pubmed: 34479714
Nat Rev Dis Primers. 2018 Aug 16;4(1):16
pubmed: 30115921
F1000Res. 2020 Feb 10;9:
pubmed: 32089834
ANZ J Surg. 2022 Jun;92(6):1377-1381
pubmed: 34723429
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005063
pubmed: 16034964
J Arthroplasty. 2021 Dec;36(12):3870-3877.e5
pubmed: 34419317
Anesth Analg. 2004 Mar;98(3):738-44, table of contents
pubmed: 14980929
Mayo Clin Proc. 2008 Mar;83(3):274-9
pubmed: 18315992
Aliment Pharmacol Ther. 2011 Apr;33(7):739-47
pubmed: 21306407
JAMA. 1994 Aug 17;272(7):519-23
pubmed: 8046805
Emerg Med J. 2019 Jan;36(1):18-21
pubmed: 30282630
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005063
pubmed: 20238336
Lancet. 2009 Feb 7;373(9662):492-501
pubmed: 19168210
Crit Care Clin. 2017 Jul;33(3):559-599
pubmed: 28601135
Clin Liver Dis (Hoboken). 2021 Sep 19;18(2):90-95
pubmed: 34584675
Curr Med Res Opin. 2002;18 Suppl 2:s5-8
pubmed: 12365830
United European Gastroenterol J. 2018 Apr;6(3):407-412
pubmed: 29774154
Eur Arch Psychiatry Clin Neurosci. 2001 Aug;251(4):185-92
pubmed: 11697583
Clin Liver Dis. 2021 May;25(2):393-417
pubmed: 33838857
JAMA Netw Open. 2022 Feb 1;5(2):e220158
pubmed: 35191968
Am J Drug Alcohol Abuse. 2018;44(4):418-425
pubmed: 28981333
Nat Rev Gastroenterol Hepatol. 2010 Sep;7(9):515-25
pubmed: 20703237
PLoS One. 2021 Dec 20;16(12):e0261443
pubmed: 34928984
Alcohol Clin Exp Res. 2004 Jan;28(1):131-6
pubmed: 14745311
Hepatology. 2020 Jan;71(1):306-333
pubmed: 31314133
J Emerg Med. 2017 Jan;52(1):34-42
pubmed: 27692840
BMJ. 1997 Nov 29;315(7120):1466
pubmed: 9418115
Am J Gastroenterol. 2018 Feb;113(2):175-194
pubmed: 29336434
Addiction. 2022 Oct;117(10):2591-2601
pubmed: 35194860
Alcohol Alcohol. 2015 Sep;50(5):509-18
pubmed: 25999438
J Addict Med. 2021 Sep-Oct 01;15(5):376-382
pubmed: 33323689
N Engl J Med. 2003 May 1;348(18):1786-95
pubmed: 12724485
JAMA. 2004 Mar 10;291(10):1238-45
pubmed: 15010446
Am J Respir Crit Care Med. 2021 Oct 1;204(7):e61-e87
pubmed: 34609257
JAMA Psychiatry. 2017 Sep 1;74(9):911-923
pubmed: 28793133
Eur Addict Res. 2017;23(4):211-218
pubmed: 28898879
J Hepatol. 2019 Feb;70(2):319-327
pubmed: 30658733
Med Clin North Am. 1997 Jul;81(4):881-907
pubmed: 9222259
Am J Gastroenterol. 2020 May;115(5):723-728
pubmed: 31658104
Gastroenterology. 2022 Oct;163(4):840-851
pubmed: 35598629
J Gen Intern Med. 1996 Jul;11(7):410-4
pubmed: 8842933
Alcohol Alcohol. 2011 Jan-Feb;46(1):68-73
pubmed: 21123365
Arch Intern Med. 2002 May 27;162(10):1117-21
pubmed: 12020181
Am J Drug Alcohol Abuse. 2009;35(3):189-92
pubmed: 19462303